Skip to main content
Christine Lovly, MD, Oncology, Nashville, TN, Vanderbilt University Medical Center

ChristineM.LovlyMDPhD

Oncology Nashville, TN

Cancer Genetics/Cancer Risk Assessment, Thoracic Cancer

Associate Professor of Medicine, Division of Hematology and Oncology Ingram Associate Professor of Cancer Research

Dr. Lovly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lovly's full profile

Already have an account?

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2012
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 2006 - 2008
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2006
  • Johns Hopkins University
    Johns Hopkins UniversityBA, Chemistry, 1993 - 1997

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2012 - 2025
  • TX State Medical License
    TX State Medical License 2023 - 2024
  • AL State Medical License
    AL State Medical License 2020 - 2020
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Asclepios Award honoring research pioneers in the fight to end lung cancer GO2 Foundation for Lung Cancer Research, 2022
  • Women Leaders in Oncology Recognition for exemplifying leadership in oncology and serving as mentors and advocate Women Leaders in Oncology, 2022
  • ECOG-ACRIN Clinical Trials Network Young Investigator Award 2021
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer  
    Christine M Lovly, Kelli L Boyd, Paula I Gonzalez-Ericsson, Cindy L Lowe, Hunter M Brown, Robert D Hoffman, Brent C Sterling, Meghan E Kapp, Douglas B Johnson, Prasad ..., medRxiv, 5/1/2020
  • Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors  
    Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM., Mod Pathol, 5/28/2015
  • Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral C...  
    Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM., Cancer Immunol Res, 5/3/2015
  • Join now to see all

Press Mentions

  • Genomic Analysis of SCLC Tumors Reveals Subtypes, Offers Cues Toward Personalized Treatments
    Genomic Analysis of SCLC Tumors Reveals Subtypes, Offers Cues Toward Personalized TreatmentsMay 11th, 2023
  • Lovly Receives Asclepios Award from GO2 for Lung Cancer
    Lovly Receives Asclepios Award from GO2 for Lung CancerDecember 8th, 2022
  • GO2 Foundation for Lung Cancer Expands Scientific Leadership Board in Effort to Double Five-Year Survival Rate by 2025
    GO2 Foundation for Lung Cancer Expands Scientific Leadership Board in Effort to Double Five-Year Survival Rate by 2025August 5th, 2021
  • Join now to see all

Hospital Affiliations